Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 5.1%

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) shares were up 5.1% during mid-day trading on Thursday . The stock traded as high as $13.89 and last traded at $13.48. Approximately 127,428 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 960,659 shares. The stock had previously closed at $12.82.

Analyst Ratings Changes

Several analysts have issued reports on STOK shares. TD Cowen raised Stoke Therapeutics from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 26th. JPMorgan Chase & Co. increased their price objective on Stoke Therapeutics from $6.00 to $13.00 and gave the company a "neutral" rating in a research note on Tuesday, March 26th. Wedbush increased their price objective on Stoke Therapeutics from $13.00 to $17.00 and gave the company an "outperform" rating in a research note on Tuesday, March 26th. Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a research note on Thursday. Finally, Needham & Company LLC increased their price objective on Stoke Therapeutics from $14.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, March 26th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $19.63.

Stoke Therapeutics Stock Down 5.0 %

The business has a fifty day simple moving average of $6.91 and a 200-day simple moving average of $5.30. The firm has a market cap of $563.47 million, a P/E ratio of -5.69 and a beta of 0.77.

Insider Activity

In related news, insider Barry Ticho sold 10,000 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $4.80, for a total transaction of $48,000.00. Following the sale, the insider now directly owns 6,981 shares of the company's stock, valued at $33,508.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Stoke Therapeutics news, CFO Stephen J. Tulipano sold 4,116 shares of the firm's stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $25,107.60. Following the transaction, the chief financial officer now directly owns 20,746 shares of the company's stock, valued at $126,550.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Barry Ticho sold 10,000 shares of the firm's stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $4.80, for a total value of $48,000.00. Following the completion of the transaction, the insider now directly owns 6,981 shares in the company, valued at $33,508.80. The disclosure for this sale can be found here. Insiders sold 32,741 shares of company stock worth $223,115 over the last three months. 12.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Swiss National Bank lifted its position in shares of Stoke Therapeutics by 8.2% during the 1st quarter. Swiss National Bank now owns 30,500 shares of the company's stock valued at $642,000 after buying an additional 2,300 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Stoke Therapeutics by 20.8% during the 1st quarter. JPMorgan Chase & Co. now owns 19,608 shares of the company's stock valued at $412,000 after buying an additional 3,374 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Stoke Therapeutics by 1.4% during the 1st quarter. Bank of New York Mellon Corp now owns 62,698 shares of the company's stock valued at $1,320,000 after buying an additional 837 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of Stoke Therapeutics by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 11,621 shares of the company's stock valued at $245,000 after buying an additional 4,289 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Stoke Therapeutics by 7.6% during the 1st quarter. Rhumbline Advisers now owns 19,345 shares of the company's stock valued at $407,000 after buying an additional 1,362 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.